CARE Ratings (CARERATING) Q3 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 24/25 earnings summary
5 Jun, 2025Executive summary
Consolidated revenue grew 22% YoY in Q3FY25 to Rs. 96.38 Cr (₹9,637.87 lakhs), and PAT rose 19% YoY to Rs. 28.37 Cr (₹2,873.72 lakhs).
Ratings business remains the main contributor, while non-ratings business grew 38% YoY, now 10.3% of revenue.
International expansion continued with subsidiaries in Africa, South Africa, Nepal, and global sovereign rating assignments.
Standalone revenue for Q3FY25 was Rs. 78.59 Cr (₹7,859.31 lakhs), with PAT at Rs. 29.46 Cr (₹2,902.96 lakhs), up 33% YoY.
Net profit for 9MFY25 was Rs. 96.10 Cr (₹9,610.35 lakhs), up from Rs. 77.83 Cr (₹7,782.89 lakhs) YoY.
Financial highlights
Consolidated EBITDA for Q3FY25 was Rs. 30.43 Cr (₹3,872.15 lakhs), margin 32%; PAT margin was 26%.
Standalone EBITDA margin was 39% in Q3FY25 and 45% for 9MFY25.
Basic EPS (consolidated) for Q3FY25 was Rs. 9.30 (₹9.30), standalone Rs. 9.85 (₹9.85).
Employee benefit expenses included ESOP charges of Rs. 41.33 lakhs (consolidated) and Rs. 26.87 lakhs (standalone) in Q3FY25.
Total consolidated assets as of Dec 31, 2024, were Rs. 912.48 Cr (₹91,247.85 lakhs).
Outlook and guidance
Management notes continued growth in ratings and strong momentum in non-ratings businesses.
Cautious optimism due to macroeconomic and regulatory factors impacting credit growth and financial markets.
Latest events from CARE Ratings
- Strong revenue and margin growth, led by ratings, with regulatory and product developments.CARERATING
Q3 25/2611 Feb 2026 - Revenue and PAT rose 19% and 16% year-over-year, led by ratings business; Board reconstituted committees.CARERATING
Q1 24/2518 Nov 2025 - Strong revenue and profit growth, global expansion, and interim dividend declared.CARERATING
Q2 24/2518 Nov 2025 - Record revenue, profit growth, and international expansion marked a strong FY25.CARERATING
Q4 24/2518 Nov 2025 - Strong profit growth, interim dividend, and strategic subsidiary stake sale in Q2 FY26.CARERATING
Q2 25/2614 Nov 2025 - Double-digit growth in income and profits, with stable governance and clean audit review.CARERATING
Q1 25/268 Aug 2025